Loading
A phase 3 trial of Trastuzumab rezetecan, Paclitaxel / nab-paclitaxel, Gemcitabine in ovarian cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Study of SHR-A1811 in Subjects With Ovarian Cancer is a phase 3 interventional study registered as NCT06828354 by Jiangsu HengRui Medicine Co., Ltd., with 300 participants planned, started 2025-03-13 and due to reach its primary completion in 2027-05. Interventions recorded: SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection, Gemcitabine Hydrochloride for Injection, Topotecan Hydrochloride for Injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Topotecan, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Paclitaxel / nab-paclitaxel.
Shares Topotecan, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Paclitaxel / nab-paclitaxel.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Paclitaxel / nab-paclitaxel.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Paclitaxel / nab-paclitaxel.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).